Profile

Heat Biologics Inc. is a US biotechnology company focused on the field of immunotherapy. This company's technology platform is called ImPACT, short for Immune Pan-Antigen Cytotoxic Therapy. The lead product HS-110 is in Phase II clinical trials and is being tested in NSCLC. It is based in Morrisville, North Carolina. ImPACT is a proposed technology platform based on live, genetically-modified, irradiated human cells which secrete a broad spectrum of cancer-associated antigens as well as an immune adjuvant called gp96. Potential advantages of this product are use as an 'allogeneic', that is, 'off-the-shelf' immunotherapy, and its applicability to a wide range of cancers. It is in phase II trials.